Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 12/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818874 | 0.84 | SLC5A2 (0.43) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL4083854 | 0.84 | SLC5A2 (0.43) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL3815130 | 0.76 | HTR2A (0.44) | HTR2CHTR2BSLC5A2SLC5A1 | |
| SCHEMBL18802133 | 0.73 | MEN1 (0.37) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL30444497 | 0.73 | MEN1 (0.37) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL16795878 | 0.73 | MEN1 (0.37) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL30445125 | 0.73 | MEN1 (0.37) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL15540266 | 0.73 | MEN1 (0.37) | HTR2CHTR2BSLC5A2CYP3A4CYP2D6 | |
| SCHEMBL5094784 | 0.72 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL15284629 | 0.72 | SLC5A2 (0.48) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091933-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073943-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | DBH, SLC6A3, SLC6A4 | HTR2C 46/4885HTR2B 44/4885SLC5A2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.